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Background: Irritable bowel syndrome (IBS) is a functional disorder of the digestive tract that causes chronic
abdominal symptoms. We evaluated the effects of Lactobacillus brevis KB290 (KB290), which has been
demonstrated to be effective at improving bowel movements and the composition of intestinal microflora, on
IBS symptoms.
Methods: We performed a placebo control double-blind cross matched trial. Thirty-five males and females
(aged 6 years and above) who had been diagnosed with IBS according to the Rome III criteria were divided into
2 groups, and after a 4-week pre-trial observation period, they were administered test capsules containing KB290
or placebo for 4 weeks (consumption period I). Then, the capsule administration was suspended for 4 weeks in
both groups (washout period), before the opposite capsules were administered for a further 4 weeks
(consumption period II). Fecal samples were collected on the first day of the pre-consumption observation
period, the last day of consumption period I, the last day of the washout period, and the last day of
consumption period II. In addition, the subjects’ IBS symptoms and quality of life (QOL) and any adverse events
that they experienced were evaluated.
Results: No significant difference in IBS symptoms was noted among the various periods. However, the mean
QOL scores were improved during the test capsule consumption.
The frequencies of watery and mushy feces were significantly lower in the test capsule consumption period than
during the pre-consumption observation period, and the frequency of abdominal pain was significantly reduced
in the test capsule consumption period compared with the other periods.
The frequency of the genus Bifidobacterium was significantly higher, and that of the genus Clostridium was
significantly lower, after the test capsule consumption than after the placebo consumption. The frequencies of
the genera Lactobacillus, Bacteroides, and Enterococcus were also investigated, but no differences in their
frequencies were detected between the placebo and test capsule consumption periods.
Conclusions: Probiotics, the safety of which has been established, are used widely in various foods and can now
be purchased readily. The results of the present study suggest that KB290 is useful for early intervention in IBS.
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Irritable bowel syndrome (IBS) is a functional disorder
of the digestive tract that causes chronic symptoms
such as abdominal pain and discomfort and abnormal
bowel movements such as diarrhea and constipation
but exhibits no organic abnormalities [1]. Its etiology
and pathology are yet to be elucidated. However, abnor-
malities in brain-gut interactions; i.e., excessive stimula-
tion of the digestive tract by the central nervous system
during stress; the disturbance of sensory and cognitive
mechanisms by disorders of the digestive tract, infec-
tion, or inflammation of the digestive tract; and changes
in the intestinal microflora have been reported to be
involved [2]. This suggests that the symptoms of IBS
can be alleviated by restoring the normal intestinal flora
and that we need to obtain a greater understanding of
intestinal microflora [3]. Analyses of the microflora in
IBS patients and healthy individuals have indicated that
differences exist between them [4], but no intestinal
bacteria that directly trigger the condition have been
identified.
Some clinical trials have indicated that probiotics are
effective at alleviating IBS symptoms and improving the
quality of life (QOL) of IBS patients [5-8]. Also, the
mechanism responsible for the beneficial effects of pro-
biotics has not been clarified although improvements
in the composition of the intestinal flora and the sup-
pression of intestinal inflammatory reactions have been
proposed as possible mechanisms [7,9].
Therefore, in this study we evaluated the effects of
Lactobacillus brevis KB290 (KB290), which is a plant-
derived strain of lactic acid bacillus isolated from
suguki (a traditional pickle produced in Kyoto) that
has been demonstrated to be effective at improving
bowel movements and the composition of the intes-
tinal microflora [10-13], on IBS symptoms and exam-
ined its effects on intestinal microflora to clarify the
mechanism by which it induces the abovementioned
improvements.Figure 1 Study design. The subjects were divided into 2 groups, and afte
containing KB290 or placebo capsules not containing KB290 at 1 capsule/d
administration was suspended for 4 weeks in both groups (washout period
administered for 4 weeks (consumption period II).Methods
Study design
The patients were randomly divided into 2 groups,
which were matched in age and gender, according to a
computer generated randomized list. After a 4-week
pre-trial observation period, they were administered test
capsules containing KB290 (freeze-dried KB290 bodies
at a dose of ≥1.0 × 1010 cfu/capsule mixed with corn
starch, maltitol syrup, hydroxypropyl methylcellulose,
and calcium stearate) or placebo capsules that did not
contain KB290 at a rate of 1 capsule/day for 4 weeks
(consumption period I). For the next 4 weeks, both
groups stopped consuming the capsules (washout
period). After the washout period, the groups were
administered the opposite capsules to those that they
had taken during the 1st consumption period for a fur-
ther 4 weeks (consumption period II). The study proto-
col was approved by the ethics committees of the
participating institutions (Figure 1).
Determination of the viable KB290 cell count
Counts of viable KB290 cells were obtained during the
preparation of the test capsules and after the end of their
administration. Then, after carefully weighing out 1.0 g
of the powder obtained from 5 capsules, it was serially
diluted using 0.1% (w/v) agar dissolved in physiological
saline, and a 50 μL suspension was applied to 15 mL
plate count agar (PCA) containing bromocresol purple
(BCP) (Eiken Chemical). The suspension was cultured at
35°C for 72 hours, and then the number of colonies was
counted. Since each capsule contained 0.34 - 0.38 g
KB290 (standard content, 0.36 g), the number of living
KB290 cells was calculated by assuming the KB290 con-
tent per capsule to be 0.34 g.
Patients
Thirty-five males and females (aged 6 years and above)
who had been diagnosed with IBS according to the
Rome III criteria [14] were selected. We calculated thatr a 4-week pre-trial observation period, administered test capsules
ay for 4 weeks (consumption period I). Then, the capsule
), and the capsules opposite to those administered first were
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tect a difference between the two consumption periods
when α= 0.05, we would need to analyze 20 patients. In
addition, we assumed a worst-case control rate of 67%.
Accordingly, we recruited 35 patients for this study. To
ensure the safety of the patients and eliminate the effects
of factors other than the test capsule on the study out-
comes, any patients who had serious disorders other
than IBS or allergies to a material contained in the test
capsule, had undergone gastrointestinal tract surgery
other than appendectomy, had participated in another
clinical study within the 3 months prior to the beginning
of this study, or who had an infectious disease were
excluded. During the patient recruitment, the intentions
of the study and its procedures were thoroughly
explained to the participants, and written consent to
participate in the study was obtained in compliance with
the Helsinki Declaration. During the study, the patients
were instructed not to eat greater than usual amounts of
foods that contained lactic acid bacilli (other than the
test capsule).
Any subjects who had been administered antibiotics
during the study period, had consumed foods that are
known to markedly affect the condition of the bowel,
that did not consume the test capsule as instructed, or
whose diary entries were defective were excluded from
the analysis.Observation of IBS symptoms
The subjects (or their parents if the subjects could not
keep a diary by themselves) kept a daily bowel move-
ments diary during the study. The recorded items were
the frequency of bowel movements, fecal properties
(amount, color, shape), physical sensations experienced
after bowel movement, time required for bowel move-
ments, abdominal symptoms (frequency of attacks of
abdominal pain), compliance with the administration
schedule, and the consumption of foods that affect the
condition of the bowel. Regarding the frequency of
bowel movements, the mean weekly number of bowel
movements was calculated separately for the pre-
consumption observation period, washout period, pla-
cebo consumption period, and test capsule consumption
period. The volume of feces was recorded in terms of
the number of chicken eggs, and the mean value per
bowel movement was calculated for each period. Con-
cerning the shape and color of feces and the physical
sensations experienced after bowel movement, mean
scores were calculated for each period. As for the time
required for bowel movements, the mean time of one
bowel movement was calculated for each period. The
frequency of attacks of abdominal pain was expressed
as the mean weekly number for each period.Analysis of fecal microflora
Fecal samples were collected on the first day of the pre-
consumption observation period, the last day of con-
sumption period I, the last day of the washout period,
and the last day of consumption period II. Immediately
after its discharge, a sample of the targeted feces was
suspended in a vessel containing a DNA preservation
medium (GCT buffer), the suspension was stored at 4°C
until analysis, and the intestinal microflora it contained
were analyzed using the terminal restriction fragment
length polymorphism (T-RFLP) method [15]. After 16S
rRNA had been extracted from the fecal suspension
using the Magtration System 12GC automatic nucleic
acid extraction machine (Precision System Science), it
was reverse transcribed using the universal primer 516F-
1510R (Life Technologies Japan) and digested using the
restriction enzyme BslI (New England Biolabs). The
digested cDNA fragments were subjected to capillary
electrophoresis using an ABI3100 genetic analyzer (Ap-
plied Biosystems), the peak pattern of the DNA frag-
ments obtained by absorptiometry at 260 nm was
compared with that of the DNA fragments of the stand-
ard, and the bacterial species present in the feces were
determined. The percentage areas of the peaks for the
genera Bifidobacterium and Clostridium relative to the
total area of all detected peaks were calculated, and the
percentage changes in the areas of these peaks were also
calculated to analyze the changes induced in the com-
position of the intestinal microflora by the test food or
placebo.
Evaluation of QOL
QOL was evaluated before and after the consumption of
the test capsule by assessing the physical activity, emo-
tional problems, social activity, pain, and overall health
state of the subjects using a 5-point scale and the Japa-
nese version of the Dartmouth COOP charts [16], and
mean scores were calculated for each period.
Evaluation of adverse events
The adverse events that occurred during the study were
evaluated on the basis of the subjects’ bowel movement
diaries and interviews conducted at the end of the study.
Abdominal pain and diarrhea, and adverse events that
might have been caused by the consumption of the test
capsule were recorded, and their frequencies during the
test capsule consumption period were compared with
those during the other periods.
Statistical analyses
The results for each evaluated item were totaled for each
subject for the pre-consumption observation period,
washout period, placebo consumption period, and test
capsule consumption period and statistically analyzed.
Figure 2 Analysis group. Thirty-five persons who volunteered to participate in the study were interviewed and all were enrolled, because none
matched any of the exclusion criteria. Eight of them dropped out during the study, and, from those who completed the study, 23 (10 males and
13 females, mean age 16.2 ± 10.5 years) were selected as an analysis group by excluding 2 with defects in diary entries and 2 in whom the
number of days with test capsule consumption was insufficient according to a premeditated procedure. The fecal microflora was analyzed in 20
subjects of the analysis group in whom data could be obtained in all periods.
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movements, fecal properties (volume, shape, color,
smell), physical sensations experienced after bowel
movement, time required for bowel movements, and fre-
quencies of the genera Bifidobacterium and Clostridium
among the fecal microflora were examined using the
paired t-test with Bonferroni’s correction. The signifi-
cance of the differences in the QOL score was examined
using the Steel-Dwass method. Statistical analyses were
performed using the SPSS software (ver15.0, IBM) at a
significance level of p<0.05.
Results
Number of living KB290 cells
The mean number of living KB290 bacteria in the test
capsule was 1.2 ± 0.3×10 [10] cfu/capsule on the day of
preparation (December 8, 2008) and 5.5 ± 0.4× 10 [9]
and 6.8 ± 0.3×10 [9] cfu/capsule on the last day of test
capsule consumption in the first (May 25, 2009) and last
(September 5, 2009) subjects, respectively. The mean of
these 3 measurements was 8.1 ± 0.4×10 [9] cfu/capsule.
Also, no KB290 bacteria were detected in the placebo
capsule at any point.
Analysis group
Thirty-five patients were interviewed and enrolled. Eight
of them dropped out during the study, and of those who
completed the study, four were excluded because of pro-
blems with their diary entries or with their complianceTable 1 IBS symptoms
Observatio
period
Frequency of bowel movement (times/week) 8.8 ± 3.5
Fecal volume (hen’s egg-size)/time 2.0 ± 1.5
Fecal color (score mean value) 3.6 ± 1.5
Feeling of bowel movement (score mean value) 3.2 ± 1.2
Amount of time for bowel movement (minutes/time) 5.5 ± 4.8
Values are expressed as Means ± SD, n = 23.with the test or placebo capsule consumption protocol,
thus 23 patients (10 males and 13 females, mean age:
16.2 ± 10.5 years) were included in the analysis (Figure 2).
The fecal microflora of 20 subjects for whom data were
obtained in all periods were analyzed. Three patients
were excluded from the fecal microflora analysis because
of problems with the fecal collection. No significant dif-
ferences were noted in any of the examined items be-
tween Groups 1 and 2.IBS symptoms
Table 1 shows our findings regarding the frequency of
bowel movements, the volume and color of the subjects’
feces, the physical sensations they experienced after
bowel movements, and the time they required for bowel
movements. No significant difference was noted in any
of these items among the various periods.
Figure 3 shows the frequencies of various fecal shapes
in each period. No significant difference in the frequency
of any fecal shape was detected between the placebo
consumption period and the washout period; however,
the frequencies of watery and mushy feces were signifi-
cantly lower in the test capsule consumption period than
in the pre-consumption observation period.
Figure 4 shows the frequency of abdominal pain in
each period. The frequency of abdominal pain was sig-
nificantly reduced in the test capsule consumption





7.8 ± 2.5 7.0 ± 3.8 8.0 ± 3.1
1.7 ± 1.1 1.8 ± 1.5 2.1 ± 1.8
3.8 ± 1.4 3.6 ± 1.4 3.5 ± 1.8
3.6 ± 0.8 3.0 ± 1.5 3.8 ± 1.3
5.9 ± 5.1 5.2 ± 5.0 5.3 ± 4.3
Figure 3 The frequencies of the appearance of various fecal shapes in each period. In the placebo consumption period, no significant
difference was noted compared with the washout period, but the frequencies of watery and mushy feces were significantly lower in the test
capsule consumption period compared with the pre-consumption observation period.
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The frequencies of the genera Bifidobacterium and
Clostridium were assessed by T-RFLP analysis. As a re-
sult, we found that the frequency of the genus Bifido-
bacterium was significantly higher, and that of the
genus Clostridium was significantly lower, after the test
capsule consumption than after the placebo consump-
tion (Figure 5). The frequencies of the genera Lactoba-
cillus (placebo : KB290 = 4.1% : 7.2%), Bacteroides
(placebo : KB290 = 33.8% : 34.3%), and EnterobacterFigure 4 The frequency of abdominal pain in each period. The frequen
consumption period compared with the other periods.(placebo : KB290 = 8.4% : 5.8%) were also investigated,
but no significant differences in their frequencies were
detected between the placebo and test capsule con-
sumption periods.
Evaluation of QOL
The Japanese version of the Dartmouth COOP Chart
indicates that the lower the score for a QOL item, the
fewer problems there are with that item. Table 2 shows
the scores for physical activity, emotional problems,cy of abdominal pain was significantly reduced in the test capsule
Figure 5 Intestinal microflora. Changes in the percentages of the genera Bifidobacterium and Clostridium were compared by T-RFLP analysis.
As a result, the percentage of the genus Bifidobacterium was significantly higher, and that of the genus Clostridium was significantly lower, after
test capsule consumption than after placeb consumption.
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significant difference was noted in any item among the
periods, the mean score for all items was reduced in the
test capsule consumption period.
Adverse events
According to the subjects’ bowel movement diary entries
and interview responses, no adverse events that were
suspected to be related to the test capsule were observed
during the study other than IBS symptoms, and no in-
crease in the frequency of IBS symptoms such as ab-
dominal pain or diarrhea was noted.
Discussion
We evaluated the effects of KB290 as a probiotic on IBS
symptoms and intestinal microflora in IBS patient. As a
result, we found that taking KB290 improved the QOL,
significantly alleviated their abdominal pain and improved
their fecal properties, and significantly changed the com-
position of their intestinal microflora.
Previous reports have suggested that some probiotics
alleviate the symptoms of IBS patients and improve their
QOL and the composition of their intestinal microflora







Physical 2.3 ± 0.9 2.5 ± 0.9 2.1 ± 0.9 2.0 ± 0.6
Emotional 2.5 ± 0.7 2.6 ± 0.9 2.5 ± 0.9 2.4 ± 0.7
Social Activities 2.3 ± 0.7 2.4 ± 0.8 2.1 ± 0.7 2.1 ± 0.7
Pain 2.8 ± 0.9 2.8 ± 1.1 2.6 ± 1.0 2.5 ± 0.9
Overall Health 3.0 ± 0.8 3.0 ± 0.8 2.9 ± 0.8 2.8 ± 0.8
Values are expressed as Means ± SD, n = 23.and Enterobacter and Clostridium, have been reported
to display lower and higher frequencies, respectively,
among the microflora of IBS patients than among those
of healthy individuals [17]. In the present study, we
focused our analysis on the frequencies of the genera
Bifidobacterium and Clostridium, which have been sug-
gested to be related to IBS symptoms. Previous studies
have shown that in healthy individuals with a tendency
for constipation the frequencies of the genera Bifidobac-
terium and Lactobacillus increase and the frequency of
the genus Enterobacter decreases after the consumption
of KB290. In this study, not only did the frequency of
the genus Bifidobacterium increase after KB290 intake,
but that of the genus Clostridium also decreased. How-
ever, no increase in the frequency of the genus Lactoba-
cillus or decrease in that of the genus Enterococcus was
detected, probably because of the large inter-individual
variations in human intestinal microflora. Human intes-
tinal microflora have been shown to change with age
and diet [18-20]. In this study, no dietary restrictions
were imposed on the subjects, and this might have been
related to the lack of change in the frequencies of these
genera after the test capsule consumption.
It is very difficult to obtain a detailed overview of in-
testinal microflora. For example, studies of intestinal
microflora composition almost exclusively rely on the
quantitative culturing of microbes from fecal samples.
However, recent nucleic acid studies have indicated that
the majority of bacteria in a variety of ecosystems are
different from those detected in culture [21]. Therefore,
only part of the intestinal microflora of IBS patients can
be examined by conventional techniques, and abnormal-
ities in intestinal microbes that cause IBS might have
been overlooked. Recently, the utility of molecular bio-
logical techniques such as RT-PCR analysis, denaturing
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pyrosequencing for analyzing the 98% of intestinal
microflora that have so far escaped analysis was evalu-
ated, but no intestinal bacterium that can directly cause
IBS has been identified [16,22-25]. In this study, the in-
testinal microflora were analyzed using the T-RFLP tech-
nique, a molecular biological method, but our analysis
primarily focused on the genera Bifidobacterium and
Clostridium. In the future, as analytical methods for in-
testinal microflora are developed, yielding a larger num-
ber of reports, intestinal bacterial species that are closely
involved in the initiation and exacerbation of IBS might
be identified.
A recent study suggested that the intestinal microflora
plays an important role in brain-gut interactions [26].
Another report indicated that intestinal microflora affect
the central nervous system [27], and changes in host be-
havior associated with changes in intestinal microflora
have been observed in animal experiments [28]. Thus,
based on recent findings regarding the functions of
microbiota, the “microbiota - gut - brain axis” has been
suggested as a new concept that describes the functional
relationship that exists among microbiota, the gut, and
the brain [29].
It was reported that intestinal inflammation is involved
in the pathogenesis of IBS and that probiotics alleviate
the symptoms of IBS by normalizing the balance of anti-
inflammatory and proinflammatory cytokines. However,
we could not determine whether KB290 affects cytokine
expression in this study [30].
In this study, KB290 was shown to alleviate IBS symp-
toms and affect the frequencies of the genera Bifidobac-
terium and Clostridium among the constituents of the
intestinal microflora, but the mechanism responsible for
this could not be clarified. In the future, it will be neces-
sary to more closely analyze the alterations in biomarker
levels associated with the changes in intestinal micro-
flora composition and symptom alleviation induced by
KB290 intake and to clarify the changes KB290 causes in
the composition of the intestinal microflora in greater
detail. However, in consideration of the recently clarified
role of intestinal microflora in the mechanisms of IBS
symptom alleviation and the etiology of the disease,
the intake of KB290, a probiotic, is considered to be
able to contribute to symptomatic improvement in
such patients.
Conclusions
Probiotics, the safety of which has been established, are
used widely in various foods and can now be purchased
readily. IBS has been reported to occur in children as
young as 6, and its symptoms, such as abdominal pain,
abdominal distension, and diarrhea, impair the QOL of
IBS patients. In addition, as it takes a long time to cureIBS, early therapeutic intervention is important. The
results of the present study suggest that KB290 is useful
for early intervention in such patients.
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